Immunocore Holdings plc 8K

Immunocore Holdings plc announced Q2 2026 results showing strong KIMMTRAK revenue growth, a solid cash position, and significant clinical pipeline progress across oncology, infectious diseases, and autoimmune programs.

On August 6, 2026, Immunocore Holdings plc reported its financial results for the quarter and six months ended June 30, 2026 and provided a broad business update, highlighting 18% year-over-year growth in KIMMTRAK (tebentafusp-tebn) net revenues to $115.9 million in Q2 2026, a near break-even quarterly net loss of $0.8 million and year-to-date net income of $12.2 million, a strong liquidity position with $880 million in cash, cash equivalents and marketable securities, and continued advancement of its oncology, infectious disease, and autoimmune pipelines, including near-complete enrollment of the Phase 3 TEBE-AM trial in advanced cutaneous melanoma, promising Phase 1 brenetafusp melanoma data supporting the Phase 3 PRISM-MEL-301 trial, progress in the ATOM adjuvant uveal melanoma trial, additional Phase 1/2 data for HIV candidate IMC-M113V, and initiation of a Phase 1 trial in type 1 diabetes with IMC-S118AI.

Filing Facts

CIK

1671927

Ticker

IMCR

Form

8K

Source Type

fda

Accession

0001671927-26-000020

Alert Tier

6